Analyzing Lite Strategy (LITS) and Its Peers

Lite Strategy (NASDAQ:LITS) is one of 451 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its rivals? We will compare Lite Strategy to similar businesses based on the strength of its analyst recommendations, institutional ownership, profitability, valuation, earnings, risk and dividends.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Lite Strategy and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1	0	0	0	1.00
Lite Strategy Competitors	4781	9955	15975	366	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 71.74%. Given Lite Strategy’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Lite Strategy has less favorable growth aspects than its rivals.

Profitability

This table compares Lite Strategy and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-69.70%	-60.80%
Lite Strategy Competitors	-2,625.49%	-359.63%	-43.39%

Valuation & Earnings

This table compares Lite Strategy and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lite Strategy	$65.30 million	-$15.94 million	-0.46
Lite Strategy Competitors	$439.18 million	-$68.87 million	-8.95

Lite Strategy’s rivals have higher revenue, but lower earnings than Lite Strategy. Lite Strategy is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Lite Strategy has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Lite Strategy’s rivals have a beta of 10.34, indicating that their average share price is 934% more volatile than the S&P 500.

Insider & Institutional Ownership

52.4% of Lite Strategy shares are held by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 3.1% of Lite Strategy shares are held by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Lite Strategy rivals beat Lite Strategy on 8 of the 13 factors compared.

About Lite Strategy

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.